Aurinia Pharmaceuticals Inc. (AUPH) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Aurinia Pharmaceuticals Inc. (AUPH) stock forecast summary
On Oct. 13, 2026, AUPH is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5379 stocks scored that day.
Aurinia Pharmaceuticals Inc. is a mid-cap company with a market capitalization of $2.18B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/E Ratio of 6.93x is the lowest of the 16 peers that report one. Its Net Margin of 100.8% is the highest of the 33 peers that report one.
A per-ticker accuracy statistic for AUPH is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, AUPH included.
Follow AUPH freeAUPH price chart and AI forecast
How AUPH ranks among 5379 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Aurinia Pharmaceuticals Inc. (AUPH) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | AUPH | Rank |
|---|---|---|
| Market Cap | $2.18B | 60/60 |
| P/E Ratio | 6.93x | 16/16 |
| P/B Ratio | 3.54x | 36/43 |
| EPS | $2.19 | – |
| Book Value/Share | $4.62 | – |
| Revenue/Share | $2.34 | – |
Profitability & Margins
| Metric | AUPH | Rank |
|---|---|---|
| ROE | 51.1% | 2/33 |
| ROA | 39.6% | 1/39 |
| ROIC | 21.8% | 1/41 |
| Gross Margin | 90.3% | 6/29 |
| Operating Margin | 48.4% | 4/33 |
| Net Margin | 100.8% | 1/33 |
| EBT Margin | 51.5% | 5/40 |
| Tax Rate | -95.9% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | AUPH | Rank |
|---|---|---|
| Current Ratio | 5.42x | 17/50 |
| Quick Ratio | 4.97x | 5/37 |
| D/E Ratio | 0.29x | 31/43 |
| Financial Leverage | 1.29x | 31/43 |
| Working Capital | $441M | 40/50 |
Cash Flow
| Metric | AUPH | Rank |
|---|---|---|
| Operating Cash Flow | $175M | 22/49 |
| OCF Growth YoY | 89.1% | 6/28 |
Operational Efficiency
| Metric | AUPH | Rank |
|---|---|---|
| Asset Turnover | 0.39x | 24/38 |
| Inventory Turnover | 0.7x | 23/27 |
| Fixed Assets Turnover | 167.3x | 6/37 |
| Days Inventory | 549 days | 5/27 |
| Payables Period | 21 days | 23/23 |
Income Statement
| Metric | AUPH | Rank |
|---|---|---|
| Total Revenue | $311M | 32/39 |
| Operating Income | $150M | 12/41 |
| Net Income | $314M | 15/40 |
| R&D Expense | $40M | 46/48 |
| Cost of Goods Sold | $30M | 22/27 |
Dividend & Shareholder Information
| Metric | AUPH | Rank |
|---|---|---|
| Shares Outstanding | 133M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $541M | 68.3% of assets |
| Cash & Short-term Investments | $180M | 22.7% of assets |
| Inventory | $45M | 5.7% of assets |
| Total Liabilities | $177M | 22.4% of assets |
| Short-term Debt | $98M | 12.4% of assets |
AUPH quarterly financials and insider trading
Aurinia Pharmaceuticals Inc. (AUPH) industry peers
Companies classified under the same SEC industry code as Aurinia Pharmaceuticals Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| AUPH Aurinia Pharmaceuticals Inc. | ▶ | $2.18B |
| LLY Eli Lilly & Co | ▶ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.61B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▼ | $178.85B |
| PFE Pfizer Inc | ▶ | $161.70B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $122.98B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $77.54B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $48.07B |
| SNY Sanofi | ▼ | $47.70B |
| RPRX Royalty Pharma Plc | ▶ | $32.53B |
| ZTS Zoetis Inc. | ▼ | $30.70B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.46B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.01B |
| ZLAB Zai Lab Ltd | ▶ | $25.93B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B |
| UTHR United Therapeutics Corp | ▼ | $23.31B |
| INSM Insmed Inc | ▼ | $21.14B |
| VTRS Viatris Inc | ▶ | $19.81B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.38B |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▲ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.09B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| ABVX Abivax S.A. | ▼ | $6.83B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.79B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.96B |
| BLRX Biolinerx Ltd. | ▼ | $5.67B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.88B |
| COGT Cogent Biosciences, Inc. | ▲ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
Where AUPH sits on the market map
Aurinia Pharmaceuticals Inc. (AUPH) stock news
Loading...
Aurinia Pharmaceuticals Inc. (AUPH) stock forecast FAQ
What is the Aurinia Pharmaceuticals Inc. (AUPH) stock forecast?
On Oct. 13, 2026, AUPH is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Aurinia Pharmaceuticals Inc. stock predictions?
A per-ticker accuracy statistic for AUPH is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Aurinia Pharmaceuticals Inc. forecasts updated?
Aurinia Pharmaceuticals Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Aurinia Pharmaceuticals Inc.'s industry peers?
60 issuers in our coverage, AUPH included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.